RecruitingPhase 2NCT06927687
Study of ZG005 in Patients With Advanced Solid Tumors
A Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of ZG005 in Patients With Advanced Solid Tumors
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Enrollment
100 participants
Start Date
Jun 13, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria5
- Fully understand the study and voluntarily sign the informed consent form.
- Male or female 18-75 years of age;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1;
- Life expectancy ≥ 12 weeks;
- Histologically or cytologically confirmed diagnosis of advanced solid tumors.
Exclusion Criteria2
- Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate that existence of the central nervous system(CNS) metastases;
- Any other malignancy within 5 years.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALZG005 for Injection
Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06927687
Related Trials
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
NCT0414562228 locations
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
NCT0485565622 locations
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT0722634918 locations
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT0612028363 locations
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT074148368 locations